NCT04471818

Ketamine or Placebo in Patients With Major Depression and Advanced Cancer

Ketamine Versus Placebo as Adjuvant Treatment for Major Depressive Disorder and Wish to Hasten Death in Advanced Cancer Patients Undergoing Palliative Care

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 19 (actual)
• Sponsor: Instituto Nacional de Cancerologia de Mexico · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

Major depression (MD) is a psychiatric disorder characterized by a persistent feeling of sadness, anhedonia or a decreased perception of pleasurable experiences, as well as appetite alterations and weight variations, sleep disorders, altered psychomotor skills, fatigue, guilt, decreased self-worth, suicidal thoughts and difficulty concentrating in a task (1). MD is a frequent complication in patients who are diagnosed with advanced cancer.

Conditions

• Major Depressive Disorder
• Advanced Cancer

Interventions

Type	Name	Description
DRUG	Ketamine	Ketamine (0.5 mg/kg) will be administered intravenously once every week to patients in the experimental arm of the study
OTHER	Placebo	Placebo (0.5 mg/kg) will be administered intravenously once every week to patients in the experimental arm of the study

Timeline

• Start date: 2019-09-19
• Primary completion: 2023-06-01
• Completion: 2023-07-30
• First posted: 2020-07-15
• Last updated: 2023-09-28

Locations

1 site across 1 country: Mexico